According to a research report “Plasma Fractionation Market size is projected to reach USD 36.7 billion by 2027 from USD 26.5 billion in 2022, at a CAGR of 6.7% during the forecast period. Market growth is driven mainly by factors such as increased application of immunoglobulins for treatment of various therapeutic areas such as hematology, neurology and pulmonology, and the use of protease inhibitors for the treatment of lung diseases and hepatic diseases that have growing incidence rate. However, the increased cost of plasma products, limited reimbursements, and the growth of recombinant alternatives are expected to restrain the growth of this market during the forecast period.
Download Report Brochure @https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=93798284
The growing use of immunoglobulins in various off-label indication and growing genetic research for characterizing and diagnosing immunodeficiency resulting in increased application of plasma fractionation products, growing geriatric population such as the population of people above 60 age expected to reach 2.1 billion by 2050, increased use of protease inhibitors such as alpha-1-antitrypsin for the treatment of lung diseases, and increased incidence of communicable diseases are the major factors driving the growth of this market.
Driver: Growing use of immunoglobulins for various therapeutic area
The increasing use of immunoglobulins for various therapeutic areas, such as autoimmune diseases, immune deficiencies, and infectious diseases, is driving the growth of the plasma fractionation market. Immunoglobulins are proteins produced by the immune system to fight against infections, allergies, and other diseases. Plasma fractionation processes are used to extract immunoglobulins from the plasma of healthy donors. These immunoglobulins are then used to treat various diseases, such as primary immunodeficiencies, autoimmune diseases, and infectious diseases. In addition, the increasing demand for immunoglobulins in the research sector is also driving the growth of the plasma fractionation market.
Restraint: Use of recombinant alternatives for certain plasma products
The use of recombinant alternatives for certain plasma products such as factor VIII, IX and von Willebrand factor is a key restraint for the growth of the plasma fractionation market. The advent of recombinant alternative products has enabled more efficient and cost-effective treatment of hemophilia, while also eliminating the risk of infections associated with the use of plasma-derived products. Numerous companies, such as Novo Nordisk, have launched recombinant alternative products in the market, which has significantly impacted the market of plasma-derived products.
Opportunity: Increased risk of communicable disease
The increasing risk of communicable diseases such as influenza, coronavirus, and HIV is expected to drive demand for plasma fractionation products. According to the World Health Organization (WHO), the number of reported cases of communicable diseases such as HIV, malaria, and tuberculosis has been increasing consistently over the past few decades. This has necessitated the need for more efficient and effective treatments and therapies for these diseases, which is expected to drive the demand for plasma fractionation products in the coming years.
In 2021, the IVIG segment accounted for the largest share of the Immunoglobulins market
Based on immunoglobulins, the plasma fractionation market is segmented into into intravenous, subcutaneous, and other immunoglobulins. IVIG accounted for the largest share of the global Immunoglobulins market in 2021. The large share of this segment is primarily attributed to its use across various disease such as on label and off lable indiacations such as dermatomyositis, Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), immune cytopenias, hypogammaglobinemia, primary antibody deficiency, vacuities, multiple sclerosis, asthma, and systemic lupus erythematosus, among other ailments. Also the shorter rapid response period of IVIG than steroids or oral immunosuppressants, the increasing investments in healthcare and the rising number of patients suffering from autoimmune diseases and other pathological conditions is key for the growth of this market segment
The pulmonology segment is expected to grow at the highest CAGR during the forecast period
Based on application, the plasma fractionation market is segmented into neurology, immunology, hematology, critical care, pulmonology, hemato-oncology, rheumatology, and other applications. In 2021, the pulmonology segment is expected to register the highest CAGR during the forecast period. Growth in this market segment is driven largely significantly increased use of protease inhibitors, such as alpha-1-antitrypsin in recent years. Also, with the rising geriatric population, the prevalence of AATD and COPD is expected to increase across the globe. With the rising incidence of target diseases, the demand for plasma-derived alpha-1-antitrypsin is expected to increase in the coming years making the pulmonogly segment the fastest growing during the forecast period.
Inquiry Before Buying @https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=93798284
North America was the largest regional market for plasma fractionation market in 2021
The global plasma fractionation market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. In 2021, North America accounted for the largest share of the plasma fractionation market, followed by Europe and the Asia Pacific. The large share of North America in the global market is attributed to the innovations in manufacturing processes such as presence of advanced virus removal technologies (such as nanofiltration), and the development of newer plasma products such as ceruloplasmin and IgA, high number of registered hemophilic patients and largest number of plasma collection center. However, the market in the Asia Pacific is expected to grow at the highest CAGR during the forecast period. This can be attributed to the growth in increasing number of hemophilic patients, as well as factors such as the increasing number of organ transplantations, modified regulations and monitoring of the implementation of procedures, policies, and guidelines to promote innovation and commercialization, increasing awareness about technologically advanced products in the region, and the improving standard of living across several APAC countries.
The plasma fractionation market is an oligopolistic market. The prominent players operating in this market include CSL (Australia), Grifols, S.A. (Spain), Shire (US), Octapharma AG (Switzerland), Kedrion S.P.A (Italy), LFB (France), Biotest AG (Germany), Sanquin (Netherlands), China Biologic Products Holdings Inc. (China), GC Pharma (Korea), Bio Products Ltd. (UK), Japan Blood Products Organization (Japan), Emergent BioSolutions (US), Shanghai Raas Blood Products Co., Ltd. (China), Intas Pharmaceuticals Ltd. (India), Bharat Serum Vaccines Limited (India).
- Baxter International Inc. acquired ChemoSera S.A. in 2022. The acquisition will expand Baxter’s portfolio of plasma fractionation products and enable the company to expand its presence in the European markets.
- Biovian Oy acquired ViroClinics Biosciences B.V. in 2022. The acquisition will expand Biovian’s plasma fractionation capabilities, increase its global presence, and enable the company to enhance its offerings in the field of plasma-derived biopharmaceuticals.
- Takeda Pharmaceutical Company Limited acquired Shire Plc in 2022. This acquisition will broaden Takeda’s product portfolio, enabling the company to expand its presence in the plasma fractionation market.
- Grifols S.A. acquired Hologic Inc. in 2022. The acquisition of Hologic & business will enable Grifols to expand its offering of plasma fractionation products and services, as well as its global presence.
- CSL Limited acquired Terumo BCT in 2023. This acquisition will enable CSL to expand its product portfolio and strengthen its position in the global plasma fractionation market.
View detailed Table of Content here@https://www.marketsandmarkets.com/Market-Reports/plasma-fractionation-market-93798284.html
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062
Visit Our Website: https://www.marketsandmarkets.com
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.
The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are moulded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.
To find out more, visit MarketsandMarkets™ or follow us on Twitter, LinkedIn and Facebook.